Subcutaneous Extension in Cutaneous Leiomyosarcoma Carries a Higher Recurrence Burden
Cutaneous leiomyosarcoma remains an uncommon soft tissue sarcoma, and the scarcity of data has left surgeons and oncologists to make surveillance decisions with limited guidance. The retrospective cohort summarized in these supplemental tables and figures addresses a practical question with real consequence at the bedside: whether disease confined to the dermis behaves differently from tumors with subcutaneous extension. The answer is clinically consequential. Recurrence differed significantly between the two groups, and subcutaneous extension emerged as the only factor associated with increased recurrence risk.
Dermal Confined Disease Versus Deeper Invasion
The study separated cLMS into two biologically and anatomically distinct groups: tumors confined to the dermis and tumors extending into subcutaneous tissue. This distinction matters because it likely reflects more than depth alone. Once a lesion crosses into the subcutaneous compartment, the tumor is no longer behaving like a purely superficial skin-based sarcoma; it has gained access to a richer tissue plane with greater room for microscopic spread and more complex surgical clearance. In practical terms, deeper extension often means a more difficult local resection and a higher chance that residual tumor cells remain after surgery.
The cohort data showed a clear divergence in recurrence rates between these two subtypes. Patients with subcutaneous extension faced significantly higher recurrence risk than those whose disease remained within the dermis. No other tested clinicopathologic variable reached the same level of association with recurrence when compared with dermis-confined disease. Age, sex, extremity location, and tumor grade were not significantly linked to recurrence in this analysis.
A single anatomic feature outweighed the rest.
Why Depth of Invasion May Matter More Than Traditional Features
For a rare sarcoma such as cLMS, clinicians often look to familiar variables like age, sex, anatomic site, and grade to estimate risk. These factors can still matter in the broader oncology setting, but this cohort suggests that the depth of invasion carries greater prognostic weight in cLMS surveillance planning. The biology is plausible. Subcutaneous extension may signal a tumor with greater invasive capacity, more aggressive local behavior, or both. It also may represent a more advanced lesion at the time of excision, even if the skin surface appearance seems modest.
Pathophysiology offers a useful framework here. The dermis and subcutis are not interchangeable compartments. Tumor cells that breach the dermis encounter a different stromal environment, more vascular and lymphatic interfaces, and a broader substrate for microscopic persistence. Even when the lesion appears completely removed, the deeper plane can harbor cells beyond the visible margin. For a disease as rare as cLMS, this kind of anatomic nuance can shape recurrence more than general descriptors of patient demographics.
Surveillance Imaging Remained Highly Variable
The second major finding concerns follow-up care. Surveillance imaging varied widely in frequency, showing no consistent practice pattern across the cohort. That variability itself is important, because it reflects the absence of a stable evidence base for post-treatment monitoring in cLMS. In rare sarcomas, imaging strategy often becomes a proxy for institutional habit rather than established risk stratification. Some patients may receive close imaging follow-up, while others undergo much less intensive monitoring, even when their underlying risk may be comparable.
Chest imaging deserves special attention in this setting because of concern for metastatic spread. The supplemental analysis examined chest x-ray use across calendar years and adjusted for the influence of changing technology by evaluating use with and without concurrent CT or MRI studies. Chest x-ray utilization declined steadily over time, matching broader diagnostic trends. Even so, the overall trajectory remained the same whether or not concurrent cross-sectional imaging was included. In other words, the downward drift in chest x-ray use was not an artifact of more CT or MRI studies being done at the same time.
That pattern suggests a real shift in surveillance habits, not a bookkeeping problem.
What the Imaging Trend Means for Clinical Practice
The steady decline in chest x-ray use may reflect changing comfort with plain radiography in oncology follow-up, especially as CT and MRI have become more embedded in routine care. Yet the dataset does not justify any single replacement strategy. What it does show is that clinicians are monitoring cLMS patients inconsistently, and the surveillance burden is being distributed in a way that lacks standardization. In rare tumors, this kind of heterogeneity can obscure recurrence patterns and make retrospective interpretation harder.
For surgeons and oncologists, the implications are straightforward. A patient with dermis-confined cLMS may not require the same intensity of surveillance as a patient whose tumor extends into the subcutaneous layer. The dataset supports a more risk-adapted approach, one driven by anatomic depth rather than by demographic or generic tumor factors. If follow-up imaging is selected too broadly, some patients may undergo unnecessary studies. If it is selected too sparingly, recurrence may be detected later than ideal.
Evidence Gaps Still Limit Standardization
Despite the clarity of the recurrence signal tied to subcutaneous extension, the evidence base remains narrow. The dataset does not provide a universal surveillance algorithm, and it does not settle the question of which imaging modality should be preferred for which patient. It also leaves open how surgical margin width, adjuvant treatment, or specific pathologic features beyond the listed variables might modify recurrence risk. Rare tumors often force clinicians to make decisions before randomized evidence is available, and cLMS is no exception.
What this cohort does provide is a stronger rationale for separating superficial dermal disease from tumors with deeper invasion when planning follow-up. The anatomy is not incidental. It appears to define prognosis, and it likely should define surveillance intensity as well. For a rare soft tissue sarcoma with limited treatment guidance, even one consistently identifiable risk factor can reshape postoperative monitoring and clinical counseling.